- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07349940
Tidlig oppdagelse av hudtumorer ved bruk av et telemedisinsk verktøy i primærhelsetjenesten (MEL)
Tidlig oppdagelse av hudtumorer ved bruk av et telemedisinverktøy i primærhelsetjenesten
The project is a national, prospective, multicenter, single-arm interventional pilot of screening skin tumors in the Czech Republic.
The primary aim of the project is to methodically prepare, implement and evaluate a pilot project that will verify the suitability of the proposed procedure of early detection of skin tumors by using a telemedicine tools and setting up and testing new methods and implementation into the system of social health care.
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
The project is a national, prospective, multicenter, single-arm interventional pilot project for skin tumors screening involving 18 general practitioners and 6 dermatology centers in the Czech Republic.
The main objective of the project is the early detection of skin tumors by general practitioners, increasing the efficiency of healthcare, and methodically preparing, implementing, and evaluating the pilot project. The project aims to verify the suitability of the proposed early detection procedure for skin tumors, as well as to establish and test new methods and integrate them into the healthcare system.
As part of the project, the procedure will be tested on a sample of approximately 1,440 individuals, which may help validate the use of telemedicine tools in healthcare. A methodology for the use of telemedicine tools will be developed, along with a framework for collaboration between general practitioners and affiliated dermatologists. Systemic changes will be proposed to enhance the efficiency of the screening process.
The project is supported by the European Social Fund (Operational Programme Employment Plus) and the state budget of the Czech Republic. It is registered with the Ministry of Labour and Social Affairs of the Czech Republic under ID: CZ.03.02.02/00/22_005/0002008.
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
- Navn: Dagmar Obšilová, Msc
- Telefonnummer: +420606429382
- E-post: dagmar.obsilova@uzis.cz
Studer Kontakt Backup
- Navn: Lucie Mandelova, Ph.D.
- Telefonnummer: +420 770190 828
- E-post: lucie.mandelova@uzis.cz
Studiesteder
-
-
-
Brno, Tsjekkia
- Har ikke rekruttert ennå
- St. Anne's University Hospital Brno
-
Ta kontakt med:
- Hana Jedličková, prof.
- E-post: hjedlic@medmuni.cz
-
Olomouc, Tsjekkia
- Rekruttering
- Olomouc University Hospital
-
Ta kontakt med:
- Zdeněk Drlík, MD
- E-post: zdenek.drlik@fnol.cz
-
Pilsen, Tsjekkia
- Har ikke rekruttert ennå
- University Hospital Pilsen
-
Ta kontakt med:
- Jan Říčař, MD, Ph.D.
- E-post: ricarj@fnplzen.cz
-
Prague, Tsjekkia
- Rekruttering
- Bulovka University Hospital
-
Ta kontakt med:
- Filip Rob, Assoc. Prof.
- E-post: filip.rob@bulovka.cz
-
Prague, Tsjekkia
- Har ikke rekruttert ennå
- University hospital Kralovske Vinohrady
-
Ta kontakt med:
- Petr Arenberger, prof.
- E-post: petr.arenberger@lf3.cuni.cz
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- at least 1 suspected lession
- phototype I or phototype II
Exclusion Criteria:
- skin lession examination by dermatologist in last 12 months
- unsigned consent to participate in the project and consent to the processing of personal data
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Adults with suspected skin lession
Pilot screening will be conducted in general practitioners' offices, where physicians will be trained to examine skin lesions using magnifying devices (dermatoscopes) and advanced telemedicine software, enabling faster diagnostics of suspicious findings. Patients with high-risk lesions will be referred to specialized dermatology centers. |
The diagnostic management of enrolled patients will be guided by standardized procedures carried out in general practitioners' offices. Physicians will be trained to identify suspicious skin lesions, capture high-resolution images using dermatoscopes, and transfer the data into advanced telemedicine software. The platform, supported by AI-driven algorithms, enables precise risk stratification of lesions and facilitates remote consultation with collaborating dermatologists. Patients with high-risk lesions will be referred to specialized dermatology centers for further examination and intervention. In cases where excision of a lesion is performed, histopathological assessment will be conducted, and results will be systematically recorded within the dedicated telemedicine platform, ensuring secure and efficient information exchange between dermatologists and general practitioners. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Potential malignancies
Tidsramme: From enrollment to the end of examination - baseline.
|
Proportion of individuals with a potential presence of malignancy (detected through the telemedicine tool). |
From enrollment to the end of examination - baseline.
|
|
Confirmed malignancies
Tidsramme: From enrollment to the end of diagnosis at 3 months.
|
Proportion of individuals with confirmed potential malignancy by a dermatologist. |
From enrollment to the end of diagnosis at 3 months.
|
|
Confirmed malignancies by histology
Tidsramme: From enrollment to the end of diagnosis at 6 months.
|
Proportion of individuals in whom the diagnosis of malignancy was confirmed histologically. |
From enrollment to the end of diagnosis at 6 months.
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Studieleder: Petr Arenberger, prof., Hospital university Kralovske Vinohrady
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- UZIS 2025/6
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .